Pasithea expands PAS-004 trial to 18 months
Pasithea Therapeutics (NASDAQ:KTTA) expanded its Phase 1/1b PAS-004 clinical trial protocol to evaluate higher 24mg and 32mg dose levels.
Pasithea Therapeutics (NASDAQ:KTTA) expanded its Phase 1/1b PAS-004 clinical trial protocol to evaluate higher 24mg and 32mg dose levels.
Anna Edwards, Guy Johnson, Tom Mackenzie and Mark Cudmore break down today's key themes for analysts and investors on "Bloomberg: The Opening Trade."
While the anti-immigration One Nation party is gaining traction in opinion polls, Australian Prime Minister Anthony Albanese has resisted calls for deeper cuts to migrant intake. That's as Australia faces its own demographic pressures with the fertility rate at a record low. Roger Wilkins of the Melbourne Institute discusses the broader challenges and implications for Australia's future on 'Bloomberg: The Asia Trade.'
Lincoln Pan, CEO at Jardine Matheson Holdings, discusses the group's strategic blueprint that includes a share buyback, boosting returns and adding exposure to developed markets. He speaks exclusively on "Bloomberg: The China Show."
BitVentures (NASDAQ:BVC) reported its unaudited financial results for the first half of fiscal 2026 ended December 31, 2025.
Japan's central bank increased its benchmark interest rate to the highest since 1995 and signaled that further policy normalization lies ahead. Bloomberg's Shery Ahn reports from Tokyo.
China's consumer spending contracted last month for the first time since the pandemic and investment deteriorated, exposing risks still facing the economy even as it benefits from booming exports and a deescalation in tensions around Iran. UBS Securities Chief China Economist Yu Song shares his analysis.
Biocon Executive Chairperson Kiran Mazumdar-Shaw says she is confident that the company's investment and capacity expansion in Insulin will make the company the top hub for the drug in the next five years. She speaks in an exclusive conversation with Bloomberg's Haslinda Amin.
U.S. data analytics provider Databricks announced an agreement on Tuesday to purchase cybersecurity startup Panther Labs.
John Rogers, Ariel Investments founder, chair, CIO and co-CEO, says MSG stocks have not reflected the value of the Knicks or the Rangers during an interview with Romaine Bostick and Katie Greifeld on "Bloomberg The Close."
Jeff Simmons, Elanco Animal Health President & CEO, discusses the emerging threat of screwworm infections spreading beyond the initial control zone in Texas, with at least 12 confirmed cases including eight heads of cattle. Simmons reassured viewers that while the pest is expected to spread, it can be managed effectively through current interventions such as the release of sterile flies to reduce the screwworm population. He speaks with Romaine Bostick & Katie Greifeld on "The Close."
Libby Cantrill, PIMCO Head of Public Policy, discussed the recent developments in negotiations involving Iran, emphasizing that what has been achieved is more of a detente than a comprehensive deal. She highlighted the uncertainty surrounding key issues such as Iran's nuclear program, funding of proxies, and the stance of regional players like Israel. She speaks with Romaine Bostick & Katie Greifeld on "The Close."